Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion type Assertion NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_head.
- NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion wasGeneratedBy ECO_0000203 NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_provenance.
- NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion wasDerivedFrom befree-20150227 NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_provenance.
- NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion SIO_000772 23658459 NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_provenance.
- NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion evidence source_evidence_literature NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_provenance.
- NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_provenance.